Announced

Henry Schein to acquire a majority stake in Biotech Dental.

Synopsis

Henry Schein, a solutions company for health care professionals, agreed to acquire a majority stake in Biotech Dental, provider of end-to-end dental solutions. Financial terms were not disclosed. “Henry Schein and Biotech Dental are committed to offering customers best-in-class, user-friendly, customer-centric solutions based on open architecture that help improve patient outcomes. Henry Schein will, over time, incorporate Biotech’s Nemotec software as part of our solutions offering, including integrating Biotech’s software solutions with Henry Schein One’s industry-leading practice management software solutions to create a leading end-to-end clinical system and to help dental practitioners streamline their clinical as well as administrative workflow,” Stanley M. Bergman, Henry Schein Chairman and CEO.

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US